PNC Financial Services Group’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
PNC Financial Services Group's DNTH Position: Q3 2026 in Review
PNC Financial Services Group increased its Dianthus Therapeutics (DNTH) stake by 2.1% in Q3 2026, buying an estimated $85.9K and bringing the position to 40,301 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #891.
PNC Financial Services Group first reported a position in DNTH in Q1 2024 and has held it in 11 quarters since. The position peaked at $3.85M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- PNC Financial Services Group held 40,301 shares of Dianthus Therapeutics worth $3.55M as of Q3 2026.
- PNC Financial Services Group bought 828 Dianthus Therapeutics shares in Q3 2026, an estimated $85.9K.
- Dianthus Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #891 holding.
- PNC Financial Services Group first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 11 quarters since.
- PNC Financial Services Group's Dianthus Therapeutics position peaked at $3.85M in Q2 2026.
- 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.